Novocure Shares Drop 10% After Phase 3 Glioblastoma Trial Misses Endpoint
NVCR•Shares of Novocure dropped 10% after its 981-patient Phase 3 TRIDENT trial in glioblastoma showed median overall survival of 17.7 months in the early-start arm versus 17.5 months in the maintenance-start arm, missing primary endpoint (HR 0.953, p=0.519). The study confirmed a consistent safety profile and one-year survival above 70%.
1. Phase 3 TRIDENT Trial Results
Novocure enrolled 981 glioblastoma patients randomized to early TTFields start during chemoradiation versus standard maintenance-start. The median overall survival was 17.7 months for early start versus 17.5 months for maintenance, with a hazard ratio of 0.953 and p-value of 0.519, missing the primary endpoint.
2. Survival Outcomes
One-year survival rates reached 70.9% in the early-start arm and 72.0% in the maintenance-start arm. Longer-term survival at two and three years was 33.9% and 22.5% for early start versus 31.6% and 18.4% for maintenance start, respectively.
3. Safety Profile
The trial confirmed that earlier TTFields therapy was well tolerated, with device-related adverse events consistent with previous studies. No new safety concerns were reported.
4. Market Impact
Shares of Novocure fell 10% in trading following the trial failure, reflecting investor disappointment. The stock movement underscores concerns over near-term growth prospects without an expanded survival benefit.
